Occupational Therapists in Fort Sill, OK Accepting Medicare
6 Occupational Therapists found. Showing 1 - 6
 Nadine Raymond Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 4301 Wilson St, Fort Sill, OK 73503 Phone: 580-558-8673 |
Deborah E-c Bachrach, OTR/L Occupational Therapist Medicare: Medicare Enrolled Practice Location: 4778 Sandoval Rd # B, Fort Sill, OK 73503 Phone: 907-229-3984 |
Suzanne Cline, ORT/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 4301 Wilson St, Fort Sill, OK 73503 Phone: 520-249-6658 |
Courtney Anne Livoti, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 4301 Wilson St, Fort Sill, OK 73503 Phone: 580-558-8620 |
Ms. Andrea Christine Lohmann, PA, OTR, CHT Occupational Therapist Medicare: Accepting Medicare Assignments Practice Location: 4301 Wilson St, Fort Sill, OK 73503 Phone: 214-668-4947 |
Mrs. Margaret Theresa Bleckler, OTR Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 2640 Miner Rd, Fort Sill, OK 73503 Phone: 508-585-5600 |
News Archive
Meridian Bioscience first quarter net sales decrease 12% to $37.3 million
Net sales for the first quarter of fiscal 2011 were $37,263,000 as compared to $42,457,000 for the same period of the prior fiscal year, a decrease of 12%. Net earnings for the first quarter of fiscal 2011 were $6,025,000, or $0.15 per diluted share, both decreases of 32% from the first quarter of fiscal 2010. Diluted common shares outstanding for the first quarter of fiscal 2011 and 2010 were 41,294,000 and 41,185,000, respectively.
New cancer study finds benefit in old therapy
Cancer patients who used a 5,000-year-old combination of gentle exercise and meditation experienced significantly higher wellbeing levels, improved cognitive functioning and less inflammation compared to a control group, new University of Sydney research has found.
Omeros submits investigational new drug to initiate OMS721 Phase 2 clinical program
Omeros Corporation today announced that it has submitted to the U.S. Food and Drug Administration (FDA) an investigational new drug (IND) application to initiate the Phase 2 clinical program for OMS721, the company's lead human monoclonal antibody targeting mannan-binding lectin‑associated serine protease-2 (MASP-2), the key regulator of the lectin pathway of the immune system.
Stem cell transplant improves survival among scleroderma patients
Scleroderma with internal organ involvement is a debilitating and lethal autoimmune disorder with few effective treatments. But a study led by Duke Health researchers has found new cause for optimism using an aggressive stem cell transplant regimen.
› Verified 9 days ago
Physical Therapists
Optometrists
Occupational Therapists
Chiropractors
Audiologists
Podiatrists
Speech-Language Pathologists